

**References to be placed on the Docket for CP2002P-0025 CP-1**

1. Statement of Karen Midthun, M.D., Director, Office of Vaccine Research and Review, CBER, FDA before the Committee on Government Reform, United States House of Representatives, December 10, 2002.
2. Ball LK, Ball R, Pratt RD, An assessment of thimerosal use in childhood vaccines, Pediatrics 2001; 1147-1154.
3. Thimerosal in Vaccines. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Updated March 21, 2005. Available: <http://www.fda.gov/cber/vaccine/thimerosal.htm>
4. Thimerosal-Containing Vaccines and Neurodevelopmental Disorders, Institute of Medicine (IOM), Washington, D.C.: National Academy Press; 2001.
5. Immunization Safety Review: Vaccine and Autism, Institute of Medicine (IOM), (Executive Summary, at 4) (emphasis in original), Washington, D.C.: National Academy Press; 2004.
6. Plotkin, Stanley A., et al, Vaccines, 4<sup>th</sup> Edition, 2004.
7. Prevention and Control of Influenza: Recommendations and Reports, CDC's Advisory Committee on Immunization Practices (ACIP), April 25, 2003. Available: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5208a1.htm>

2002P 0025

REF 1